Cytokines as Biomarkers of Treatment Response to IFNβ in Relapsing-Remitting Multiple Sclerosis

Background. MS patients show a remarkable heterogeneity in their response to disease modifying treatments. Given the need for early treatment initiation and the diversity of available options, a predictive marker that indicates good or poor response to treatment is highly desirable. Objective. To fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Dimisianos, Nikolaos, Rodi, Maria, Kalavrizioti, Dimitra, Georgiou, Vasileios, Papathanasopoulos, Panagiotis, Mouzaki, Athanasia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134814/
https://www.ncbi.nlm.nih.gov/pubmed/25152817
http://dx.doi.org/10.1155/2014/436764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134814/
https://www.ncbi.nlm.nih.gov/pubmed/25152817
http://dx.doi.org/10.1155/2014/436764

Ejemplares similares